Amgen Inc. (AMGN)

192.49
3.50 1.80
NASDAQ : Health Technology
Prev Close 189.04
Open 188.34
Day Low/High 187.12 / 192.63
52 Wk Low/High 163.31 / 210.19
Volume 2.52M
Avg Volume 2.66M
Exchange NASDAQ
Shares Outstanding 637.22M
Market Cap 122.07B
EPS 2.70
P/E Ratio 49.88
Div & Yield 5.28 (2.67%)

Latest News

Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires

Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires

New Pledge is in Addition to $250,000 Contribution to Ventura County Community Foundation's Conejo Valley Victims Fund

Your Game Plan: Cramer's 'Mad Money' Recap (Friday 11/9/18)

Your Game Plan: Cramer's 'Mad Money' Recap (Friday 11/9/18)

Jim Cramer says the Fed is overreacting and he isn't worried about oil prices. Here's your game plan for next week.

Weekly Roundup

Markets had another volatile week as trade tensions crossed currents with a U.S. midterm election that was closer than many had predicted.

Video: Jim's Daily Rundown for Thursday

Jim discusses Aimovig and Amgen, Anadarko and Schlumberger, the Federal Reserve, Disney ahead of earnings, and more!

Reviewing Some Winners After the Election Results

We think defense stocks, among other sectors, can rally.

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018

Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018

Additional Analyses of Real-World Data Will Explore Treatment Utilization and Understanding of Treatment Goals in Patients at High Risk for Cardiovascular Events

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease

Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714

Microsoft, Ross Stores, Pitney Bowes: 'Mad Money' Lightning Round

Microsoft, Ross Stores, Pitney Bowes: 'Mad Money' Lightning Round

Jim Cramer takes a look at Microsoft, Ross Stores, Pitney Bowes, Alnylam Pharmaceuticals, Golar LNG, ResMed and more.

Market Whiplash: Cramer's 'Mad Money' Recap (Friday 11/2/18)

Market Whiplash: Cramer's 'Mad Money' Recap (Friday 11/2/18)

Jim Cramer breaks down the day's roller-coaster action amid confusing news. Plus, he's got your game plan for next week.

Weekly Roundup

Markets experienced more volatility this week.

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Stephen 'Sarge' Guilfoyle gives you a rundown of what's in his portfolio as the new month gets rolling.

Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018

Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018

First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE® Immunotherapy Platform Across Hematologic Malignancies

Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program

Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program

Through a new $21 Million, Four-Year Investment, Amgen Scholars Program to Reach Additional 1,500 Undergraduates

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Video: Jim's Daily Rundown for Wednesday

Jim discusses Facebook's earnings, Apple before earnings on Thursday, Anadarko Petroleum, DowDuPont, Amgen and more!

Amgen Beats on Quarterly Earnings, Revenue

Revenue of $5.9 billion topped the consensus of $5.77 billion, and adjusted earnings per share of $3.69 exceeded the consensus of $3.45.

Amgen Reports Third Quarter 2018 Financial Results

Amgen Reports Third Quarter 2018 Financial Results

THOUSAND OAKS, Calif., Oct.

Video: Jim's Daily Rundown

Jim discusses BP and Anadarko Petroleum, what to expect from Facebook earnings, the IBM and Red Hat deal, and more!

Staying Long Apple Into Tuesday's Product Launch: Market Recon

Staying Long Apple Into Tuesday's Product Launch: Market Recon

My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.

What to Watch When Facebook Reports Earnings

What to Watch When Facebook Reports Earnings

Overwhelmed by the earnings bonanza? Investors should be keeping an eye on when Facebook releases earnings. Listen to the podcast.

Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease

Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease

Repatha Results in Consistent Reductions in LDL-C Levels and Cardiovascular Events in Patients Independent of Kidney Function

Weekly Roundup

Markets were volatile again this week.

Amgen Announces Webcast Of 2018 Third Quarter Financial Results

Amgen Announces Webcast Of 2018 Third Quarter Financial Results

THOUSAND OAKS, Calif., Oct.

Trimming Nordstrom, Buying More Amgen

As we did once before this week, we are treating JWN as a source of funds.

Red Hat, Take-Two Interactive, Sage Therapeutics: 'Mad Money' Lightning Round

Red Hat, Take-Two Interactive, Sage Therapeutics: 'Mad Money' Lightning Round

Jim Cramer weighs in on Red Hat, Take-Two Interactive, Sage Therapeutics, Mazor Robotics, Donnelly Financial Solutions.

Untangling the Spin: Cramer's 'Mad Money' Recap (Thursday 10/25/18)

Untangling the Spin: Cramer's 'Mad Money' Recap (Thursday 10/25/18)

Jim Cramer says investors need context about what's really happening with earnings, tariffs, the Fed, and in Washington.

Buying More Amgen

Among other factors, we want to improve our cost basis here when we can.

TheStreet Quant Rating: B (Buy)